Search

Displaying results 4051 - 4060 of 6835 in total
  1. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593].

  2. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  3. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  4. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

  5. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).

  6. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells. … SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma.

  7. Drug

    Carbon black

    go.drugbank.com/drugs/DB11980
    Investigational

    [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416] … Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function.

    Synonyms: DC BLACK NO. 2, D&C black no. 2
  8. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    Trials of this drug have most likely been discontinued by the manufacturer. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  9. Drug

    (5E,7E,9)-decatrien-2-one

    go.drugbank.com/drugs/DB15618
    Experimental

    An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5Z,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]

  10. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. … Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer